Weight & Metabolic
Why Does Weight Come Back After Stopping Semaglutide?
The short answer
In the trial that followed people for a year after they stopped, participants regained about two-thirds of the weight they had lost. A separate trial of tirzepatide found the same pattern. Researchers describe this as evidence that obesity behaves like a chronic condition — the drug suppresses appetite while it is being taken, and appetite returns when it is withdrawn.
Quick answers
- What is it?
- This covers why people who stop taking semaglutide or tirzepatide tend to regain most of the weight they lost, based on two trials that specifically tracked what happens after stopping.
- Why are people interested in it?
- People considering or already on these drugs want to know realistically what happens if they ever stop, since that shapes how they think about long-term use.
- What has actually been studied?
- The STEP 1 trial extension, which followed 327 people for a year after stopping semaglutide and lifestyle support, and SURMOUNT-4, which randomized 670 people who had already lost weight on tirzepatide to either continue the drug or switch to placebo.
- How strong is the evidence?
- Clean and direct evidence from two purpose-built randomized trials: STEP 1 extension participants regained 11.6 of their 17.3 percentage points of lost weight within a year, and in SURMOUNT-4 the placebo-switched group gained back 14.0% while the continuing group kept losing.
- What don't we know yet?
- Whether tapering the dose changes the regain pattern, whether a lower maintenance dose works, why some people regain far less than others, what happens beyond the roughly one-year follow-up window, and whether diet or exercise habits built during treatment change the regain trajectory.
- Where can I read the original research?
- Sources at the bottom of this page: Wilding JPH, et al., Diabetes, Obesity & Metabolism, 2022 (STEP 1 trial extension); and Aronne LJ, et al., JAMA, 2024 (SURMOUNT-4).
The short answer: In the trial that followed people for a full year after stopping, participants regained about two-thirds of the weight they had lost. A separate trial testing tirzepatide found the same pattern — and the people who stayed on the drug kept losing. Researchers read this as evidence that obesity behaves like a chronic condition rather than a course of treatment with an endpoint.
What the research shows
The semaglutide data
STEP 1 was one of the largest weight-loss drug trials ever run: 1,961 adults with obesity and no diabetes, randomized to weekly semaglutide 2.4 mg or placebo for 68 weeks. Average weight change was −14.9% on semaglutide versus −2.4% on placebo.
What matters for this question is what happened next. A subset of 327 participants who completed the full 68 weeks were followed for another year after all treatment stopped — the drug and the lifestyle program both.
In that group, average weight loss during treatment had been 17.3%. One year off treatment, they had regained 11.6 percentage points of it. Net loss from where they started: 5.6%.
Cardiometabolic markers followed the weight. Improvements in blood pressure, lipids, and other risk factors that appeared during treatment moved back toward baseline over the same year.
The tirzepatide data
SURMOUNT-4 was built specifically to test this question, and its design makes the answer hard to argue with.
All 783 participants took tirzepatide openly for 36 weeks and lost an average of 20.9%. Then 670 of them were randomized — half continued on tirzepatide, half switched to placebo, neither group knowing which.
Over the following 52 weeks:
- The group that continued lost another 5.5%
- The group switched to placebo gained 14.0%
By the end, 89.5% of those still on tirzepatide had held onto at least 80% of their original loss. Among those switched to placebo, 16.6% had.
Because the only variable that changed between the two groups was the drug, this is about as clean a demonstration as trial design allows.
Why researchers say this happens
The trial authors frame the finding the same way in both papers: it reflects the chronicity of obesity. The drugs work by reducing appetite and slowing gastric emptying while they are present in the body. They do not appear to reset the biology that made weight loss difficult in the first place. When the drug clears, the underlying appetite signaling returns, and so does the weight.
The STEP 1 extension authors concluded that ongoing treatment is required to maintain the improvements — in weight and in the cardiometabolic markers that came with it.
What we don't know yet
This is where the published evidence runs out, and it is worth being clear about it.
Whether tapering changes anything. Both trials stopped treatment outright. No trial has directly compared abrupt discontinuation against a gradual taper, so there is no evidence base for the tapering protocols circulating online.
Whether a lower maintenance dose works. SURMOUNT-4 compared full-dose continuation against nothing. The middle ground — a reduced maintenance dose — has not been tested this way.
Why some people regain far less than others. The averages hide wide variation. In the STEP 1 extension the standard deviation on that 11.6-point regain was 7.7, meaning some participants regained very little and others regained more than they lost. What separates them is not established.
What happens past two years. These extensions ran roughly a year post-treatment. Longer-horizon outcomes are not yet published.
Whether behavior during treatment changes the outcome. Whether resistance training, protein intake, or other habits built during treatment alter the regain trajectory has not been tested in a randomized withdrawal design.
Sources
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism, 2022;24(8):1553–1564. DOI
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021;384(11):989–1002. DOI
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024;331(1):38–48. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism | Evidence Index: semaglutide · tirzepatide
Sources
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.